Cravath’s New York Office Moves to Two Manhattan West
Matthew L. Ploszek focuses his practice on mergers and acquisitions, corporate governance and general corporate matters.
Mr. Ploszek’s clients have included AerCap, Ashland, Brightline, Brookfield, Brunswick Corporation, Cable One, Cincinnati Bell, CommScope, Evolent Health, Ferroglobe, Fortress Transportation and Infrastructure Investors, Forward Air, IBM, IFF, Janssen, Lindsay Goldberg, Martin Marietta, Olin, Owl Rock, Parker Hannifin, Pinnacle Foods, Radius Global Infrastructure, Spectranetics and Unilever.
Mr. Ploszek’s notable transactions include representing:
Mr. Ploszek has been recognized for his work in private equity by The Legal 500 US and IFLR1000 and he has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. Ploszek is from St. Charles, Illinois. He received a B.A. summa cum laude from the University of Notre Dame in 2007, where he was elected to Phi Beta Kappa, a J.D. cum laude from the University of Pennsylvania Law School in 2014, where he was an associate editor of the Journal of Constitutional Law, and an M.B.A. with honors from the Wharton School of the University of Pennsylvania in 2014.
Mr. Ploszek joined Cravath in 2014 and was elected a partner in 2021.
Mr. Ploszek’s notable transactions include representing:
Mr. Ploszek has been recognized for his work in private equity by The Legal 500 US and IFLR1000 and he has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. Ploszek is from St. Charles, Illinois. He received a B.A. summa cum laude from the University of Notre Dame in 2007, where he was elected to Phi Beta Kappa, a J.D. cum laude from the University of Pennsylvania Law School in 2014, where he was an associate editor of the Journal of Constitutional Law, and an M.B.A. with honors from the Wharton School of the University of Pennsylvania in 2014.
Mr. Ploszek joined Cravath in 2014 and was elected a partner in 2021.
American Bar Association
IFLR1000
Lawdragon
The Legal 500 US
Deals & Cases
October 07, 2024
On October 7, 2024, Iris Financial, a Euronext Amsterdam-listed company focused on the financial services sector, and Younited S.A. (“Younited”), a leading European consumer credit business, announced they have signed a business combination agreement. Iris Financial will inject between €150 and €200 million of capital into Younited in consideration for newly-issued shares of Younited. At completion of the Combination (prior to the share capital increase), Iris Financial will own at least 95% of Younited, with any remaining Younited shares to be acquired by Iris after completion pursuant to drag-along provisions contained in Younited’s existing shareholder agreement and upon the exercise of put-call rights by Iris or certain historical Younited shareholders. Iris Financial will be renamed “Younited Financial” and will remain listed on Euronext Amsterdam while applying for an additional listing on Euronext Paris. Cravath is representing Iris Financial as U.S. counsel in connection with the transaction.
Deals & Cases
August 08, 2024
On August 8, 2024, private investment firm Lindsay Goldberg and Golden State Foods, one of the largest diversified suppliers to the foodservice and retail industries, announced that they have entered into an agreement for Lindsay Goldberg to acquire a controlling interest in Golden State Foods. Cravath is representing Lindsay Goldberg in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
January 24, 2024
On January 22, 2024, Forward Air Corporation (“Forward”) announced an agreement with Omni Logistics, LLC (“Omni”), a private company that is majority owned by Ridgemont Equity Partners and EVE Partners, LLC, to amend the terms of the existing merger agreement relating to their previously announced acquisition. This agreement ends the litigation between the parties, which will now be dismissed. Under the terms of the amended merger agreement, Omni shareholders will receive $20 million in cash, instead of the $150 million initially agreed, and 35% of Forward’s pro forma common equity (on a fully‑diluted, as‑converted basis), as compared to the 37.7% of Forward’s pro forma common equity (on a fully‑diluted, as‑converted basis) contemplated by the original agreement. Cravath is representing Forward in connection with the transaction and related litigation.
Matthew L. Ploszek focuses his practice on mergers and acquisitions, corporate governance and general corporate matters.
Mr. Ploszek’s clients have included AerCap, Ashland, Brightline, Brookfield, Brunswick Corporation, Cable One, Cincinnati Bell, CommScope, Evolent Health, Ferroglobe, Fortress Transportation and Infrastructure Investors, Forward Air, IBM, IFF, Janssen, Lindsay Goldberg, Martin Marietta, Olin, Owl Rock, Parker Hannifin, Pinnacle Foods, Radius Global Infrastructure, Spectranetics and Unilever.
Mr. Ploszek’s notable transactions include representing:
Mr. Ploszek has been recognized for his work in private equity by The Legal 500 US and IFLR1000 and he has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. Ploszek is from St. Charles, Illinois. He received a B.A. summa cum laude from the University of Notre Dame in 2007, where he was elected to Phi Beta Kappa, a J.D. cum laude from the University of Pennsylvania Law School in 2014, where he was an associate editor of the Journal of Constitutional Law, and an M.B.A. with honors from the Wharton School of the University of Pennsylvania in 2014.
Mr. Ploszek joined Cravath in 2014 and was elected a partner in 2021.
Mr. Ploszek’s notable transactions include representing:
Mr. Ploszek has been recognized for his work in private equity by The Legal 500 US and IFLR1000 and he has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. Ploszek is from St. Charles, Illinois. He received a B.A. summa cum laude from the University of Notre Dame in 2007, where he was elected to Phi Beta Kappa, a J.D. cum laude from the University of Pennsylvania Law School in 2014, where he was an associate editor of the Journal of Constitutional Law, and an M.B.A. with honors from the Wharton School of the University of Pennsylvania in 2014.
Mr. Ploszek joined Cravath in 2014 and was elected a partner in 2021.
American Bar Association
IFLR1000
Lawdragon
The Legal 500 US
Deals & Cases
October 07, 2024
On October 7, 2024, Iris Financial, a Euronext Amsterdam-listed company focused on the financial services sector, and Younited S.A. (“Younited”), a leading European consumer credit business, announced they have signed a business combination agreement. Iris Financial will inject between €150 and €200 million of capital into Younited in consideration for newly-issued shares of Younited. At completion of the Combination (prior to the share capital increase), Iris Financial will own at least 95% of Younited, with any remaining Younited shares to be acquired by Iris after completion pursuant to drag-along provisions contained in Younited’s existing shareholder agreement and upon the exercise of put-call rights by Iris or certain historical Younited shareholders. Iris Financial will be renamed “Younited Financial” and will remain listed on Euronext Amsterdam while applying for an additional listing on Euronext Paris. Cravath is representing Iris Financial as U.S. counsel in connection with the transaction.
Deals & Cases
August 08, 2024
On August 8, 2024, private investment firm Lindsay Goldberg and Golden State Foods, one of the largest diversified suppliers to the foodservice and retail industries, announced that they have entered into an agreement for Lindsay Goldberg to acquire a controlling interest in Golden State Foods. Cravath is representing Lindsay Goldberg in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
January 24, 2024
On January 22, 2024, Forward Air Corporation (“Forward”) announced an agreement with Omni Logistics, LLC (“Omni”), a private company that is majority owned by Ridgemont Equity Partners and EVE Partners, LLC, to amend the terms of the existing merger agreement relating to their previously announced acquisition. This agreement ends the litigation between the parties, which will now be dismissed. Under the terms of the amended merger agreement, Omni shareholders will receive $20 million in cash, instead of the $150 million initially agreed, and 35% of Forward’s pro forma common equity (on a fully‑diluted, as‑converted basis), as compared to the 37.7% of Forward’s pro forma common equity (on a fully‑diluted, as‑converted basis) contemplated by the original agreement. Cravath is representing Forward in connection with the transaction and related litigation.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.